Receptor tyrosine kinase inhibitors

Current Opinion in Investigational Drugs

Volumn 2, Issue 2, 2001, Pages 280-286

  Haluska, P ^a   Adjei, A A ^a  

^a MAYO CLINIC   (United States)

Author keywords

EGF; FGF; Growth factors; PDGF; Signal transduction; VEGF

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 3 [(4,5 DIMETHYL 1H PYRROL 2 YL)METHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; ANTINEOPLASTIC AGENT; BIBX 1382; CANERTINIB; CETUXIMAB; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; GEFITINIB; GROWTH FACTOR; IMATINIB; MIDOSTAURIN; N (4 BROMO 2 FLUOROPHENYL) 6 METHOXY 7 [2 (1H 1,2,3 TRIAZOL 1 YL)ETHOXY] 4 QUINAZOLINAMINE; PD 0183805; PELITINIB; PLATELET DERIVED GROWTH FACTOR; PROTEIN TYROSINE KINASE INHIBITOR; TRASTUZUMAB; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; VATALANIB;

ANGIOGENESIS; CANCER; CELL DIFFERENTIATION; CELL GROWTH; CLINICAL TRIAL; DRUG INHIBITION; DRUG TARGETING; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; METASTASIS; MITOGENICITY; ONCOGENESIS AND MALIGNANT TRANSFORMATION; RASH; REVIEW; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 0035116613     PISSN: 09678298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Therapeutic intervention and signaling
2. Signaling through phosphoinositide 3-kinases: The lipids take centre stage
3. SH2 and SH3 domains: Elements that control interactions of cytoplasmic signaling proteins
4. Oncoprotein networks
5. Signal transduction pathway targets for anticancer drug discovery
6. Signal transduction by receptors with tyrosine kinase activity
7. Protein tyrosine kinases and cancer
8. Identification of a member of the MAPKKK family as a potential mediator of TGF-beta signal transduction
9. A sarcoma of the fowl transmissible by an agent separable from the tumor cells
10. Some possible effects of nursing on the mammary gland tumor incidence in mice
11. 'Spontaneous' leukemia developing in C3H mice following inoculation, in infancy, with AK-leukemic extracts or AK-embryos
12. Determining factor in the capacity of Rous sarcoma virus to induce tumors in mammals
13. Characterization of the avian sarcoma virus protein p60src
14. Protein kinase activity associated with the avian sarcoma virus src gene product
15. The purified product of the transforming gene of avian sarcoma virus phosphorylates tyrosine
16. Evidence that the phosphorylation of tyrosine is essential for cellular transformation by Rous sarcoma virus
17. Stimulation of the proliferation of chicken fibroblasts by folic acid or a serum factor(s) in a plasma-containing medium
18. Roles of calcium, plasma, and folic acid in the control of proliferation of normal and Rous sarcoma virus-infected chicken fibroblasts
19. A platelet-dependent serum factor that stimulates the proliferation of arterial smooth muscle cells in vitro
20. Platelets as a source of fibroblast growth-promoting activity
21. sis of simian sarcoma virus
22. Simian sarcoma virus onc gene, v-sis, is derived from the gene (or genes) encoding a platelet-derived growth factor
23. Close similarity of epidermal growth factor and v-erbB oncogene protein sequences
24. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells
25. EGF receptor
26. The epidermal growth factor receptor and its inhibition in cancer therapy
27. Epidermal growth factor-alpha: A more potent angiogenic mediator than epidermal growth factor
28. Expression of growth factors, growth-inhibiting factors, and their receptors in invasive breast cancer. Correlations with proliferation and angiogenesis
29. Functional intactness of stimulatory and inhibitory autocrine loops in human renal carcinoma cell lines of the clear cell type
30. Co-expression of heparin-binding EGF-like growth factor and related peptides in human gastric carcinoma
31. Expression of heparin-binding epidermal growth factor in human hepatocellular carcinoma
32. Epidermal growth factor-related peptides and their receptors in human malignancies
33. Tyrosine kinase inhibitors: From the emergence of targets to their clinical development
34. Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo
35. The epidermal growth factor receptor and the prognosis of bladder cancer
36. Epidermal growth factor receptor (EGFr); results of a 6 year follow-up study in operable breast cancer with emphasis on the node negative subgroup
37. Immunohistochemical evidence of autocrine growth factors in adenocarcinoma of the human lung
38. Expression of EGF, TGF-alpha and EGFR in squamous cell lung carcinomas
39. Epidermal growth factor receptor and prognosis in human breast cancer: A prospective study
40. Prognostic relevance of epidermal growth factor receptor (EGF-R) and c-neu/erbB2 expression in glioblastomas (GBMs)
41. Prognostic significance of transforming growth factor-alpha in human esophageal carcinoma. Implication for the autocrine proliferation
42. Intermittent oral ZD1839 (Iressa), a novel epidermal growth factor receptor tyrosine kinase inhibitor, shows evidence of good tolerability and activity: Final results from a phase I study
43. Continuous administration of ZD1839 (Iressa), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with 5 selected tumor types: Evidence of activity and good tolerability
44. Investigation of the effects of CP-358,774 on various human tumor specimens taken directly from patients
45. A phase II multi-center study of the epidermal growth factor receptor tyrosine kinase inhibitor CP-358,774 in patients with advanced squamous cell carcinoma of the head and neck
46. A phase II trial of the epidermal growth factor tyrosine kinase inhibitor CP-358,774 following platinum-based chemotherapy in patients with advanced non-small cell lung cancer
47. Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: Progression from reversible to irreversible inhibitors
48. EKB-569: A new irreversible inhibitor of epidermal growth factor receptor tyrosine kinase for the treatment of cancer
49. Combinatorial chemoprevention of intestinal neoplasia
50. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis
51. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer
52. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types
53. Phase I dose-escalating trial of SU5416, a novel angiogenesis inhibitor in patients with advanced malignancies
54. A phase I trial of the VEGF inhibitor SU5416, incorporating dynamic contrast MRI assessment of vascular permeability
55. Antiangiogenic strategies and agents in clinical trials
56. Current clinical trials administering the antiangiogenesis agent SU5416
57. The design and synthesis of a novel, orally active VEGF receptor tyrosine kinase inhibitor
58. ZD4190: An orally administered inhibitor of VEGF signaling with pan-xenograft anti-tumor activity
59. Effect of the VEGF receptor tyrosine kinase inhibitor ZD4190 on vascular endothelial permeability
60. Inhibitors of protein kinases: CGP41251, a protein kinase inhibitor with potential as an anticancer agent
61. Therapy of VEGF-dependent human ovarian carcinoma by oral administration of CGP 79787/ZK222584, an inhibitor of the VEGF receptor tyrosine kinase
62. Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)-phenyl]-5-methylisoxazole-4-carboxamide
63. AstraZeneca plans Faslodex first-line advanced breast cancer sNDA for 2002
64. Fibroblast growth factors and their inhibitors
65. Structural and functional diversity in the FGF receptor multigene family
66. Structural interactions of fibroblast growth factor receptor with its ligands
67. Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor
68. Inhibition of cell growth and tumorigenesis of human glioblastoma cells by neutralizing antibody against human basic fibroblast growth factor
69. Differential expression of two fibroblast growth factor-receptor genes is associated with malignant progression in human astrocytomas
70. Tyrosine kinase inhibitors
71. Phase I dose-escalating trial of oral SU6668, a novel multiple receptor tyrosine kinase inhibitor in patients with selected advanced malignancies